CN104350069B - 中和rsv、mpv和pvm的抗体和其应用 - Google Patents

中和rsv、mpv和pvm的抗体和其应用 Download PDF

Info

Publication number
CN104350069B
CN104350069B CN201380026218.8A CN201380026218A CN104350069B CN 104350069 B CN104350069 B CN 104350069B CN 201380026218 A CN201380026218 A CN 201380026218A CN 104350069 B CN104350069 B CN 104350069B
Authority
CN
China
Prior art keywords
antibody
rsv
mpv
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380026218.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104350069A (zh
Inventor
D·柯蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Priority to CN201711120146.XA priority Critical patent/CN107880121B/zh
Publication of CN104350069A publication Critical patent/CN104350069A/zh
Application granted granted Critical
Publication of CN104350069B publication Critical patent/CN104350069B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201380026218.8A 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用 Active CN104350069B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711120146.XA CN107880121B (zh) 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261613197P 2012-03-20 2012-03-20
US61/613,197 2012-03-20
US201261655310P 2012-06-04 2012-06-04
US61/655,310 2012-06-04
PCT/IB2013/000627 WO2013140247A1 (en) 2012-03-20 2013-03-14 Antibodies that neutralize rsv, mpv and pvm and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711120146.XA Division CN107880121B (zh) 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用

Publications (2)

Publication Number Publication Date
CN104350069A CN104350069A (zh) 2015-02-11
CN104350069B true CN104350069B (zh) 2017-12-01

Family

ID=48471031

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380026218.8A Active CN104350069B (zh) 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用
CN201711120146.XA Active CN107880121B (zh) 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711120146.XA Active CN107880121B (zh) 2012-03-20 2013-03-14 中和rsv、mpv和pvm的抗体和其应用

Country Status (16)

Country Link
US (4) US9498531B2 (enExample)
EP (1) EP2828293B1 (enExample)
JP (4) JP6445423B2 (enExample)
KR (1) KR102149069B1 (enExample)
CN (2) CN104350069B (enExample)
AU (1) AU2013237087B2 (enExample)
BR (1) BR112014023063A2 (enExample)
CA (1) CA2865856C (enExample)
DK (1) DK2828293T3 (enExample)
EA (1) EA030319B1 (enExample)
ES (1) ES2657470T3 (enExample)
IL (1) IL234710A (enExample)
IN (1) IN2014DN07299A (enExample)
NZ (1) NZ630920A (enExample)
PL (1) PL2828293T3 (enExample)
WO (1) WO2013140247A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2828293T3 (pl) 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
WO2020160171A1 (en) * 2019-01-29 2020-08-06 Sanford Burnham Prebys Medical Discovery Institute Topically formulated antibody compositions for reducing pathogen transmission and methods of using same
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
TW202246317A (zh) * 2021-02-09 2022-12-01 瑞士商休曼生物醫藥股份公司 針對呼吸道融合病毒及其他副黏液病毒的抗體以及使用其之方法
AU2022227761A1 (en) * 2021-02-26 2023-09-28 Fred Hutchinson Cancer Center Protective antibodies against respiratory viral infections
CN115466326B (zh) * 2021-06-11 2024-06-04 中国科学院微生物研究所 一种呼吸道合胞病毒的人源单克隆抗体及其应用
WO2025015321A1 (en) * 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
WO2010149743A3 (en) * 2009-06-24 2011-03-10 Id Biomedical Corporation Of Quebec Vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
EP1473037A1 (en) 2003-05-02 2004-11-03 Vironovative B.V. Treatment of hPMV infections with Ribavirin
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2350128B1 (en) 2008-10-22 2014-10-01 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
TWI539963B (zh) * 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
PL2828293T3 (pl) * 2012-03-20 2018-03-30 Humabs Biomed S.A. Przeciwciała, które neutralizują RSV, MPV i PVM oraz ich zastosowania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228367A1 (en) * 2005-04-08 2006-10-12 Medimmune, Inc. Antibodies against mammalian metapneumovirus
WO2010149743A3 (en) * 2009-06-24 2011-03-10 Id Biomedical Corporation Of Quebec Vaccine

Also Published As

Publication number Publication date
ES2657470T3 (es) 2018-03-05
US20210115114A1 (en) 2021-04-22
JP2015514068A (ja) 2015-05-18
US20140037648A1 (en) 2014-02-06
EP2828293B1 (en) 2017-10-25
US20170121393A1 (en) 2017-05-04
EA201491724A1 (ru) 2015-01-30
EP2828293A1 (en) 2015-01-28
CA2865856C (en) 2023-03-14
WO2013140247A1 (en) 2013-09-26
IL234710A (en) 2016-12-29
JP7069251B2 (ja) 2022-05-17
BR112014023063A2 (pt) 2017-07-18
JP6722264B2 (ja) 2020-07-15
CN104350069A (zh) 2015-02-11
JP2022132244A (ja) 2022-09-07
IN2014DN07299A (enExample) 2015-04-24
CN107880121B (zh) 2022-02-18
US10072071B2 (en) 2018-09-11
NZ630920A (en) 2017-01-27
US9498531B2 (en) 2016-11-22
KR102149069B1 (ko) 2020-08-28
CN107880121A (zh) 2018-04-06
KR20140135259A (ko) 2014-11-25
EA030319B1 (ru) 2018-07-31
JP6445423B2 (ja) 2018-12-26
HK1206367A1 (en) 2016-01-08
US20190153073A1 (en) 2019-05-23
JP2020182464A (ja) 2020-11-12
AU2013237087A1 (en) 2014-09-18
AU2013237087B2 (en) 2017-07-20
PL2828293T3 (pl) 2018-03-30
US11421020B2 (en) 2022-08-23
CA2865856A1 (en) 2013-09-26
JP2019076091A (ja) 2019-05-23
DK2828293T3 (en) 2018-01-08

Similar Documents

Publication Publication Date Title
US11421020B2 (en) Antibodies that neutralize RSV, MPV and PVM and uses thereof
AU2009275226B2 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
US11370829B2 (en) Antibodies that potently neutralize RSV and uses thereof
HK1206367B (en) Antibodies that neutralize rsv, mpv and pvm and uses thereof
EA039682B1 (ru) Антитела, нейтрализующие rsv, mpv и pvm, и их применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170831

Address after: Bellinzona

Applicant after: HUMABS BIOMED SA

Address before: Bellinzona

Applicant before: HUMABS BIOMED SA

Applicant before: CORTI DAVIDE

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant